Olaparib, after first round of chemotherapy, improves progression-free survival in ovarian cancer


Women with ovarian cancer with changes in the BRCA1 or BRCA2 gene appear to live for about three years longer without the disease returning, if they are given an additional maintenance treatment of the drug olaparib, a so-called PARP inhibitor, following their surgery and first chemotherapy.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.